Open AccessProlonged use of bedaquiline in two patients with pulmonary extensively drug-resistant tuberculosis: Two case reports
Author(s) -
Jingtao Gao,
Li Xie,
Li Ma,
Wei Shu,
Lijie Zhang,
Yu-Jia Ning,
Shuduo Xie,
Yuhong Liu,
Mengqiu Gao
Publication year - 2021
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v9.i10.2326
Subject(s) - bedaquiline , medicine , tuberculosis , pulmonary tuberculosis , drug , drug resistance , surgery , pharmacology , mycobacterium tuberculosis , pathology , microbiology and biotechnology , biology
Bedaquiline is among the prioritized drugs recommended by the World Health Organization for the treatment of extensively drug-resistant tuberculosis (XDR-TB). Many patients have not achieved better clinical improvement after bedaquiline is stopped at 24 wk. However, there is no recommendation or guideline on bedaquiline administration beyond 24 wk, which is an important consideration when balancing the benefit of prognosis for XDR-TB against the uncertain safety concerning the newer antibiotics.